Annovis Bio, Inc. financial data

Symbol
ANVS on NYSE
Industry
Pharmaceutical Preparations
Location
101 Lindenwood Drive, Suite 225, Malvern, PA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
QR Pharma, Inc. (to 3/15/2019)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 345 % -57.8%
Debt-to-equity -637 % -3834%
Return On Equity 2.78K %
Return On Assets -517 % -370%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.1M shares +44.8%
Common Stock, Shares, Outstanding 11.7M shares +30.1%
Entity Public Float 91.5M USD +44.2%
Common Stock, Value, Issued 1.17K USD +29.9%
Weighted Average Number of Shares Outstanding, Basic 11.3M shares +26.3%
Weighted Average Number of Shares Outstanding, Diluted 11.3M shares +26.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 35M USD +32.8%
General and Administrative Expense 5.84M USD -23.6%
Operating Income (Loss) -40.9M USD -20.2%
Nonoperating Income (Expense) -2.14M USD -467%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43M USD -28.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -43M USD -28.7%
Earnings Per Share, Basic -4.51 USD/shares -13%
Earnings Per Share, Diluted -4.97 USD/shares -28.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4M USD -74.6%
Assets, Current 7.81M USD -69.4%
Assets 5.05M USD -77.9%
Accounts Payable, Current 3.39M USD +189%
Employee-related Liabilities, Current 387K USD +48.8%
Liabilities, Current 4.06M USD +95.6%
Liabilities 6.8M USD +228%
Retained Earnings (Accumulated Deficit) -116M USD -58.7%
Stockholders' Equity Attributable to Parent -1.75M USD -108%
Liabilities and Equity 5.05M USD -77.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +39.5%
Net Cash Provided by (Used in) Financing Activities 4.42M USD +59675%
Common Stock, Shares Authorized 70M shares 0%
Common Stock, Shares, Issued 11.7M shares +30.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.62M USD +77.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4M USD -74.6%
Deferred Tax Assets, Valuation Allowance 30.1M USD +63.1%
Deferred Tax Assets, Gross 30.1M USD +63.1%
Deferred Tax Assets, Operating Loss Carryforwards 9.61M USD +21.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Additional Paid in Capital 115M USD +21.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.6M USD +1.59%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%